Online citations, reference lists, and bibliographies.

The Role Of The Gastrointestinal Tract In Calcium Homeostasis And Bone Remodeling

J. Keller, T. Schinke
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
While skeletal biology was approached in a rather isolated fashion in the past, an increasing understanding of the interplay between extraskeletal organs and bone remodeling has been obtained in recent years. This review will discuss recent advances in the field that have shed light on how the gastrointestinal tract and bone relate to each other. In particular, the importance of the GI tract in maintaining calcium homeostasis and skeletal integrity will be reviewed as impaired gastric acid production represents a major public health problem with possible implications for sufficient calcium absorption. Osteoporosis, the most prevalent bone disease worldwide, is caused not only by intrinsic defects affecting bone cell differentiation and function but also by a large set of extrinsic factors including hormonal disturbances, malnutrition, and iatrogenic drug application. Given the skeletal requirements of calcium, amino acids, and energy for bone turnover and renewal, it is not surprising that the gastrointestinal (GI) tract is of major importance for skeletal integrity.
This paper references
Comparison of prevalence of chronic atrophic gastritis in Japan, China, Tanzania, and the Dominican Republic
K Aoki (2005)
10.1007/s00223-008-9170-1
Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults
E. Yu (2008)
10.1080/003655201750422585
Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.
G. Cui (2001)
10.1159/000023499
Gastrectomy and Osteomalacia: An Association Not to Be Forgotten
Z. Efstathiadou (1999)
10.1007/s00198-003-1567-0
Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women
A. Kenny (2003)
10.1097/00003086-198512000-00036
Rickets and osteopetrosis: the osteosclerotic (oc) mouse.
R. Banco (1985)
10.1056/NEJM198507113130202
Calcium absorption and achlorhydria.
R. Recker (1985)
10.1080/07315724.1995.10718522
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C. Serfaty-Lacrosniere (1995)
10.1023/A:1006803615430
The osteocalcin gene: a model for multiple parameters of skeletal-specific transcriptional control
G. Stein (2004)
Pathophysiology and Treatment
G. Herbel (2000)
10.1016/S0016-5085(99)70453-1
Gastric H(+),K(+)-adenosine triphosphatase beta subunit is required for normal function, development, and membrane structure of mouse parietal cells.
K. L. Scarff (1999)
10.1001/JAMA.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1152/ajpgi.00496.2010
Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases.
F. Ghishan (2011)
Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism
AI Sharara (2012)
10.1056/NEJMRA040952
Mechanisms of disease osteopetrosis
J. Tolar (2004)
10.1016/j.amjmed.2011.01.007
Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Elaine W. Yu (2011)
10.1136/gut.32.11.1303
Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry.
S. Bisballe (1991)
10.1016/S0002-9610(97)00123-2
High prevalence of bone disorders after gastrectomy.
T. Zittel (1997)
10.1080/07315724.2001.10719038
Absorbability and Cost Effectiveness in Calcium Supplementation
R. Heaney (2001)
10.1007/s11894-001-0072-x
The dynamics of gastritis
E. Kuipers (2001)
10.1007/s00223-008-9188-4
Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole
C. Roux (2008)
10.1111/j.1749-6632.2009.05226.x
Vitamin D action : Lessons learned from genetic mouse models.
D. Goltzman (2010)
10.1038/ajg.2009.44
The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism
K. Insogna (2009)
Osteoporosis, metabolic aberrations, and increased risk for vertebral fractures after partial gastrectomy.
D. Mellström (1993)
10.1007/s00198-011-1778-8
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies
Q. Wu (2011)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.1007/s00198-009-0891-4
Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates
F. Vries (2009)
10.1515/CCLM.1999.114
Low Bone Mineral Density after Total Gastrectomy in Males: a Preliminary Report Emphasizing the Possible Significance of Urinary Net Acid Excretion, Serum Gastrin and Phosphorus
A. Schmiedl (1999)
10.1016/J.CMET.2006.10.010
ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae.
F. Elefteriou (2006)
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
10.1016/j.bone.2010.12.015
Meta-analysis: risk of fractures with acid-suppressing medication.
C. Kwok (2011)
10.1016/S0016-5085(00)70004-7
Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.
M. Wolfe (2000)
10.1002/jcb.23337
Decreased bone mineral density and reduced bone quality in H(+) /K(+) ATPase beta-subunit deficient mice.
R. Fossmark (2012)
10.1097/00000658-199702000-00006
Calcium regulation and bone mass loss after total gastrectomy in pigs.
G. Maier (1997)
10.1038/70563
Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification
Y. Li (1999)
10.3748/WJG.V13.I48.6492
High prevalence of osteoporosis in patients with gastric adenocarcinoma following gastrectomy.
J. Lim (2007)
10.1086/338450
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.
R. Little (2002)
10.1038/nm.2388
Lrp5 functions in bone to regulate bone mass
Y. Cui (2011)
10.1038/nature10763
The contribution of bone to whole-organism physiology
G. Karsenty (2012)
10.1016/1043-2760(95)00126-3
Calcitriol-resistant rickets due to vitamin D receptor defects
Z. Hochberg (1995)
10.1016/S0092-8674(04)00344-7
ATF4 Is a Substrate of RSK2 and an Essential Regulator of Osteoblast Biology Implication for Coffin-Lowry Syndrome
X. Yang (2004)
10.1007/BF00235526
The influence of partial gastrectomy on biochemical parameters of bone metabolism and bone density
H. Resch (1992)
10.1016/0016-0032(47)90471-7
The paradox of plenty
H. Leech
10.1136/bmj.e372
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study
H. Khalili (2012)
10.1136/jmg.2005.036673
Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment
A. Del Fattore (2005)
10.1007/S11926-008-0017-6
Osteoporosis epidemiology update
Zoe A. Cole (2008)
10.1093/ndt/10.8.1376
Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.
G. Graziani (1995)
10.3748/WJG.V16.I19.2323
Safety of the long-term use of proton pump inhibitors.
A. Thomson (2010)
10.1016/0009-9236(95)90245-7
Studies of the oral bioavailability of alendronate
B. Gertz (1995)
10.1210/ENDO.139.10.6262
Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice.
Y. Li (1998)
10.1056/NEJMOA013444
High bone density due to a mutation in LDL-receptor-related protein 5.
L. Boyden (2002)
10.1152/physrev.1986.66.4.855
Cells of bone: proliferation, differentiation, and hormonal regulation.
P. Nijweide (1986)
10.3275/7925
Catabolic and anabolic actions of parathyroid hormone on the skeleton
B. C. Silva (2011)
10.1007/BF02556841
Omeprazole, a specific inhibitor of H+−K+-ATPase, inhibits bone resorptionin vitro
J. Tuukkanen (2007)
10.1038/77131
Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis
A. Frattini (2000)
10.1053/j.gastro.2010.03.055
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
D. Corley (2010)
10.1016/S0022-3476(05)81919-5
Calcium therapy for calcitriol-resistant rickets.
Z. Hochberg (1992)
10.1016/S0016-5085(97)90000-7
Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice.
N. Langhans (1997)
10.1016/j.gene.2011.10.044
Update on Wnt signaling in bone cell biology and bone disease.
D. G. Monroe (2012)
and bone disease
VK Yadav (2008)
10.1007/s10620-010-1560-3
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
E. Sheen (2010)
10.1038/nm.1963
Impaired gastric acidification negatively affects calcium homeostasis and bone mass
T. Schinke (2009)
10.1016/J.AMJMED.2005.02.007
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
10.1097/00003086-199309000-00008
Osteopetrorickets. The paradox of plenty. Pathophysiology and treatment.
F. Kaplan (1993)
10.1620/tjem.156.237
Bone metabolism following gastric surgery: microdensitometry and single-photon absorptiometry.
M. Imamura (1988)
10.1016/S8756-3282(00)00404-X
Bone mineral metabolism after total gastrectomy.
J. T. Heiskanen (2001)
10.1056/nejm200209193471216
High bone density due to a mutation in LDL-receptor-related protein 5.
R. D. Little (2002)
10.1016/j.drudis.2009.03.014
Proton pump inhibitors: actions and reactions.
J. Mullin (2009)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
10.1210/en.140.11.4982
Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses.
M. Amling (1999)
10.1016/S0084-3741(09)79290-X
Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum
B. Clarke (2009)
10.1016/j.bone.2012.05.018
Antidepressant medications and osteoporosis.
R. Rizzoli (2012)
10.1016/0005-2736(91)90238-4
Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
J. P. Mattsson (1991)
10.1001/archinternmed.2011.20
Proton pump inhibitor use and the antifracture efficacy of alendronate.
B. Abrahamsen (2011)
10.3949/ccjm.77a.10087
Proton pump inhibitor side effects and drug interactions: Much ado about nothing?
Ryan D. Madanick (2011)
10.1007/s002230010025
Osteoporosis After Gastrectomy: Bone Mineral Density of Lumbar Spine Assessed by Dual-Energy X-ray Absorptiometry
Y. Adachi (2000)
Severe Hypocalcemia after Intravenous Bisphosphonate Therapy in Occult Vitamin D Deficiency
E. Mantzouranis (2010)
10.1159/000064290
Calcium and Phosphate Plasma Levels in Dialysis Patients after Dietary Ca-P Overload
G. Graziani (2002)
10.1016/J.ANNEPIDEM.2004.11.002
Comparison of prevalence of chronic atrophic gastritis in Japan, China, Tanzania, and the Dominican Republic.
K. Aoki (2005)
10.3109/00365529109103982
Characteristics of gastric mucosa which precede occurrence of gastric malignancy: results of long-term follow-up of three family samples.
T. Ihamäki (1991)
10.1002/jbmr.166
Do Proton Pump Inhibitors Decrease Calcium Absorption?
K. Hansen (2010)
10.1007/s00774-009-0119-x
A review of drug-induced hypocalcemia
G. Liamis (2009)
10.1177/0115426507022003286
Calcium supplementation in clinical practice: a review of forms, doses, and indications.
Deborah A Straub (2007)
10.1136/gut.32.11.1298
Importance of the stomach in maintaining calcium homoeostasis in the rat.
J. Axelson (1991)
10.1002/PHAR.1007
Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Yuen Ting Lau (2012)
10.1001/archinternmed.2010.94
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
S. Gray (2010)
10.1007/s00198-012-2095-6
Bone metabolism in anorexia nervosa: molecular pathways and current treatment modalities
D. Howgate (2012)
10.4158/EP.12.1.48
Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.
N. Maalouf (2006)
10.1146/annurev.nu.09.070189.001415
Hypochlorhydria: a factor in nutrition.
Z. Kassarjian (1989)
10.1007/s00198-012-2112-9
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study
L-A. Fraser (2012)
10.1177/009127009903901106
Pharmacokinetics of calcium absorption from two commercial calcium supplements.
H. Heller (1999)
10.1001/ARCHINTE.167.2.188
Effect of selective serotonin reuptake inhibitors on the risk of fracture.
J. Richards (2007)
10.3109/00365529609009126
Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study.
J. Valle (1996)
10.1016/S0140-6736(97)09528-7
Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people
B. Liu (1998)
10.1002/bjs.1800790413
Metabolic bone disease following gastrectomy: Assessment by dual energy X‐ray absorptiometry
K. Inoue (1992)
10.1007/BF01352010
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
K. Mizunashi (2005)
10.1016/S0092-8674(01)00571-2
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Y. Gong (2001)
10.1016/j.metabol.2012.09.011
Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study.
Ala I Sharara (2013)
Update on Wnt signaling in
DG Monroe (2012)
10.1053/j.gastro.2009.11.014
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
L. Targownik (2010)
10.1007/s00198-011-1574-5
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors
Christian Roux (2011)
10.1016/S0002-9440(10)63798-4
Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis.
A. Taranta (2003)
10.3109/00365520903434117
Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis?
P. Sipponen (2010)
10.1046/J.1525-1594.1998.06200.X
Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.
P. Hardy (1998)



This paper is referenced by
10.1016/j.soard.2013.07.014
Cross-sectional long-term micronutrient deficiencies after sleeve gastrectomy versus Roux-en-Y gastric bypass: a pilot study.
A. Alexandrou (2014)
10.1515/iss-2016-0025
Bone biology in the elderly: clinical importance for fracture treatment
T. Rolvien (2016)
10.1007/s00393-014-1510-0
Kalzium und Vitamin D in der Osteologie
Michael Amling (2014)
10.1007/s10620-015-3576-1
Serologically Determined Gastric Mucosal Condition Is a Predictive Factor for Osteoporosis in Japanese Men
Shigeto Mizuno (2015)
10.1007/s00198-014-2965-1
Calcium gluconate supplementation is effective to balance calcium homeostasis in patients with gastrectomy
M. Krause (2014)
10.1007/s11695-017-2932-y
High Incidence of Secondary Hyperparathyroidism in Bariatric Patients: Comparing Different Procedures
Jih-Hua Wei (2017)
10.1007/s11596-019-2040-4
Absorption Characteristics of Novel Compound Calcium Carbonate Granules: Effects of Gastric Acid Deficiency and Exogenous Weak Acids
Hong-dan Chen (2019)
10.1002/cbf.3379
Melatonin supports alendronate in preserving bone matrix and prevents gastric inflammation in ovariectomized rats
E. B. Gürler (2019)
10.1007/s00198-015-3168-0
Use of proton pump inhibitors is associated with fractures in young adults: a population-based study
D. Freedberg (2015)
10.2215/CJN.09750913
Renal control of calcium, phosphate, and magnesium homeostasis.
J. Blaine (2015)
10.1111/jgs.13661
Hyperparathyroidism Associated with Long-Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults.
A. Hinson (2015)
10.1007/978-3-319-71181-2
Mandibular Implant Prostheses
E. Emami (2018)
10.3109/08941939.2014.943857
Bsm1 Vitamin D Receptor Polymorphism and Calcium Homeostasis Following Bariatric Surgery
A. Alexandrou (2015)
10.1007/s00132-015-3135-7
Vitamin-D-Stoffwechsel des Knochens
Florian Barvencik (2015)
10.1007/S40355-015-0050-4
Kalzium und Vitamin D in der Osteologie: Calcium and vitamin D in osteology
Michael Amling (2015)
10.1002/bit.27171
Strategy for achieving standardized bone models
Mikhael Hadida (2019)
10.1155/2015/984935
Determinants of Secondary Hyperparathyroidism in Bariatric Patients after Roux-en-Y Gastric Bypass or Sleeve Gastrectomy: A Pilot Study
Andreas N. Alexandrou (2015)
Biotechnology and Bioengineering
J. Schmitt (2019)
10.1007/s11298-015-1220-1
Kalzium und Vitamin D in der Osteologie
Michael Amling (2015)
10.1007/978-3-319-71181-2_4
Pharmacological Risk Assessment for Dental Implants
X. Wu (2018)
10.4172/2329-9509.1000160
The Importance of a Correct Diet in Preventing Osteoporosis
Pavone (2015)
10.1007/s00068-014-0374-y
A holistic hip fracture approach: individualized diagnosis and treatment after surgery
Michael Amling (2014)
10.14264/uql.2016.971
Investigations into the bone health of men on the prostate cancer continuum: A focus on osteoporosis and health behaviours
Annie-Claude M Lassemillante (2016)
10.1007/s00360-019-01255-3
Calcium homeostasis during hibernation and in mechanical environments disrupting calcium homeostasis
Yasir Arfat (2020)
10.1007/s00113-015-0104-x
Kalzium und Vitamin D im Knochenstoffwechsel
Michael Amling (2015)
10.1371/journal.pone.0162645
Analysis of Patients with Helicobacter pylori Infection and the Subsequent Risk of Developing Osteoporosis after Eradication Therapy: A Nationwide Population-Based Cohort Study
Hong-Mo Shih (2016)
10.31665/JFB.2018.3153
Gut microbiota, probiotics, prebiotics and bone health: a review
Nan Shang (2018)
Semantic Scholar Logo Some data provided by SemanticScholar